Clinical trial · Observational
Optical Genome Mapping in Hematological Malignancies
NCT05009537CI-TRIAL-00053309CARTOGENrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| ALL | Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
| MDS | Myelodysplastic Syndrome | CURATED_BROADER | 0.80 |
| Other Hematologic Malignant Neoplasms | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Establish the diagnostic potential of optical genome mapping in patients with suspected hematologic cancer
- timeFrame
- 2021-2026
- description
- identification of anomalies by mapping identical to those identified by combining conventional cytogenetics and FISH.
Secondary outcomes (2)
- measure
- identification of new chromosomal abnormalities of clinical relevance.
- timeFrame
- 2021-2026
- measure
- identification of new chromosomal anomalies involved in oncogenic pathways
- timeFrame
- 2021-2026
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Minor/Major Patients * Patients with suspected hemopathies for whom we receive a sample for diagnosis in the chromosomal genetics laboratory or for whom a diagnosis of hemopathy has already been made. * No objection made or consent given Exclusion Criteria: * Patients under judicial protection (guardianship, curatorship, ...), * Refusal to participate
References
Publications (0)
Data not yet available
No reference posted for this study.